Addex Therapeutics Ltd. (ADXN)
About Addex Therapeutics Ltd.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $7.4M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $7.4M
- Shares outstanding
- 1.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 29, 2020
Addex Therapeutics Ltd. (ADXN) Stock Price
- Trading 48% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Addex Therapeutics Ltd..
Write a review
News about Addex Therapeutics Ltd.
News & sentiment via Polygon.io
Addex Therapeutics Ltd.: frequently asked questions
Is Addex Therapeutics Ltd. an American company?
Addex Therapeutics Ltd. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Addex Therapeutics Ltd. publicly traded?
Yes — Addex Therapeutics Ltd. is a publicly traded company. Its stock trades under the ticker symbol ADXN on the NASDAQ.
What does Addex Therapeutics Ltd. do?
Addex Therapeutics Ltd. is an American Pharmaceuticals company in the Health & Beauty sector.
